Natera (NTRA) Given New $27.00 Price Target at Piper Jaffray Companies

Natera (NASDAQ:NTRA) had its price target lifted by Piper Jaffray Companies to $27.00 in a research note released on Thursday, August 9th, The Fly reports. They currently have an overweight rating on the medical research company’s stock.

Several other brokerages have also recently issued reports on NTRA. Morgan Stanley boosted their price objective on Natera from $16.00 to $20.00 and gave the company an overweight rating in a report on Monday, June 25th. ValuEngine raised Natera from a hold rating to a buy rating in a report on Wednesday, May 2nd. Robert W. Baird upped their price target on Natera from $17.00 to $20.00 and gave the stock an outperform rating in a report on Thursday, June 28th. BidaskClub raised Natera from a strong sell rating to a sell rating in a report on Wednesday, April 11th. Finally, Craig Hallum set a $23.00 price target on Natera and gave the stock a positive rating in a report on Thursday, June 28th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $23.14.

NTRA traded up $0.18 on Thursday, reaching $27.64. 519,700 shares of the stock were exchanged, compared to its average volume of 337,395. The stock has a market cap of $1.72 billion, a P/E ratio of -11.52 and a beta of 2.12. The company has a debt-to-equity ratio of -3.32, a quick ratio of 1.56 and a current ratio of 1.69. Natera has a fifty-two week low of $8.60 and a fifty-two week high of $29.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.55). The business had revenue of $63.07 million during the quarter, compared to analysts’ expectations of $61.71 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.55) EPS. analysts predict that Natera will post -2.05 EPS for the current fiscal year.

In other news, COO Steven Leonard Chapman sold 86,919 shares of the company’s stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $18.00, for a total value of $1,564,542.00. Following the completion of the sale, the chief operating officer now directly owns 3,588 shares in the company, valued at $64,584. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 26,870 shares of the company’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $18.29, for a total value of $491,452.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 114,436 shares of company stock valued at $2,065,020. 13.18% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Tygh Capital Management Inc. lifted its stake in Natera by 32.3% during the second quarter. Tygh Capital Management Inc. now owns 300,036 shares of the medical research company’s stock worth $5,647,000 after purchasing an additional 73,301 shares in the last quarter. Sofinnova Ventures Inc acquired a new position in Natera during the first quarter worth $28,742,000. Trexquant Investment LP acquired a new position in Natera during the first quarter worth $119,000. Schwab Charles Investment Management Inc. lifted its stake in Natera by 11.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 172,518 shares of the medical research company’s stock worth $1,600,000 after purchasing an additional 18,051 shares in the last quarter. Finally, EAM Investors LLC acquired a new position in Natera during the second quarter worth $3,868,000. Hedge funds and other institutional investors own 66.31% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: What does RSI mean?

The Fly

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply